Aptose Biosciences Inc. (TSE:APS – Get Free Report) (NASDAQ:APTO) fell 24% on Wednesday . The company traded as low as C$0.37 and last traded at C$0.38. 120,484 shares changed hands during trading, an increase of 1,333% from the average session volume of 8,405 shares. The stock had previously closed at C$0.50.
Aptose Biosciences Stock Down 9.3 %
The stock has a market capitalization of C$6.16 million, a price-to-earnings ratio of -0.06 and a beta of 1.36. The business has a 50-day moving average of C$0.52 and a 200-day moving average of C$0.85. The company has a debt-to-equity ratio of 670.80, a quick ratio of 5.41 and a current ratio of 0.80.
About Aptose Biosciences
Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.
Featured Stories
- Five stocks we like better than Aptose Biosciences
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Tesla Investors Continue to Profit From the Trump Trade
- What Are Some of the Best Large-Cap Stocks to Buy?
- MicroStrategy’s Stock Dip vs. Coinbase’s Potential Rally
- ESG Stocks, What Investors Should Know
- Netflix Ventures Into Live Sports, Driving Stock Momentum
Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
